MTOR and acute lymphoblastic leukemia: Existing therapeutic strategies under development for T-ALL predominantly focus on the modulation of dysregulated signaling pathways, including Notch, mTOR, and PI3K.17 However, these pathways are also important in the development and function of the normal hematopoietic system, and their utilization to target LSCs has resulted in side effects limiting their clinical applications.18 Hence, there is a need for innovative therapeutic approaches to effectively target LSCs in T-ALL with an enhanced safety profile and increased potential for a successful transition to clinical development.